Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Background Apixaban and rivaroxaban, both direct-acting oral anticoagulants, are being increasingly used in routine clinical practice because of their fixed dosing and favourable pharmacological profiles. Differences in the risk of recurrent venous thromboembolism and major bleeding events between the two drugs are currently unknown. We aimed to compare the effectiveness and safety of apixaban and rivaroxaban in prevention of recurrent venous thromboembolism and major bleeding events in patients with venous thromboembolism. Methods We did a retrospective cohort analysis of data from the Truven Health MarketScan commercial and Medicare Supplement claims databases in the USA. We analysed data for adult patients with newly diagnosed venous thromboembolism (deep vein thrombosis or pulmonary embolism) who were new users of apixaban or rivaroxaban between Jan 1, 2014, and Dec 31, 2016. Patients who did not initiate the study drugs within 30 days of their diagnosis, those without 12 months of continuous enrolment in medical and pharmacy benefits, and those who used other anticoagulants during the baseline period were excluded. The primary effectiveness outcome was the incidence of recurrent venous thromboembolism and the primary safety outcome was the incidence of major bleeding events. Cox-proportional hazard models after propensity score matching were used to calculate the hazard ratio (HR) and 95% CI. Findings After propensity score matching, 15 254 patients were included in the…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A total of 5 studies were included for analysis: 1 study included a review of data from a thrombophilia clinic registry, 1 study included a review of retrospective data of veterans, and 3 were database studies from the United States and Denmark.”
From Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world (2019) · cites this paper as [10]
In the citing paper
“Although the 5 selected studies 8-11,14 assessed similar efficacy end points and outcomes, they were slightly different in terms of overall design and outcome definitions (Table 1).”
From Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world (2019) · cites this paper as [10]
In the citing paper
“Various retrospective studies (database, registries) have been carried out looking at head-to-head comparisons between apixaban and rivaroxaban on VTE recurrence risk and bleeding risk. 8-11”
From Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world (2019) · cites this paper as [10]
Citations
Cites
Heart Disease and Stroke Statistics—2012 Update: A Report From the American Heart Association
Writing Group Members, Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., et al. (2012) · Circulation · doi:10.1161/cir.0b013e31823ac046 · Cited by 7,333
Heart Disease and Stroke Statistics—2010 Update: A Report From the American Heart Association
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., Ferguson, T. B., Ford, E., Furie, K., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192667 · Cited by 5,700
Tarver, T. (2014) · Journal of Consumer Health On the Internet · doi:10.1080/15398285.2014.902284 · Cited by 5,605
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
Pulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
Weitz, J. I., Lensing, A. W. A., Prins, M. H., Bauersachs, R., Beyer-Westendorf, J., Bounameaux, H., Brighton, T. A., Cohen, A. T., Davidson, B. L., Decousus, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700518 · Cited by 787
A unified approach to measuring the effect size between two groups using SAS
Yang, D., & Dalton, J. E. (2012) · Cited by 419
Frost, C., Nepal, S., Wang, J., Schuster, A., Byon, W., Boyd, R. A., Yu, Z., Shenker, A., Barrett, Y. C., Mosqueda‐Garcia, R., et al. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12106 · Cited by 286
Cited by
Lutsey, P. L., Walker, R. F., MacLehose, R. F., Alonso, Á., Adam, T. J., & Zakai, N. A. (2019) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12222 · Cited by 79
Dawwas, G. K., Leonard, C. E., Lewis, J. D., & Cuker, A. C. (2021) · Annals of Internal Medicine · doi:10.7326/m21-0717 · Cited by 83
“A limited number of observational studies have compared apixaban and rivaroxaban (9, 10), but these studies had a relatively small sample size (n= 1504 to 3000 for apixaban) or included data up to 2015, a year after apixaban was approved by the U.”
BackgroundMethodSelf-citationAryal, M. R., Gosain, R., Donato, A., Yu, H., Katel, A., Bhandari, Y., Dhital, R., & Kouides, P. A. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000572 · Cited by 62
Acute treatment of venous thromboembolism
Becattini, C., & Agnelli, G. (2020) · Blood · doi:10.1182/blood.2019001881 · Cited by 64
Lutsey, P. L., Zakai, N. A., MacLehose, R. F., Norby, F. L., Walker, R. F., Roetker, N. S., Adam, T. J., & Alonso, A. (2019) · British Journal of Haematology · doi:10.1111/bjh.15857 · Cited by 47
“…was poor (Mantha & Ansell, 2015; Sterne et al, 2017), an observational study that did not restrict to the 6-month primary treatment period (Dawwas et al, 2019), comparisons conducted in the context of atrial fibrillation (Norby & Alonso, 2017), and the observation of increased menstrual…”
Background
Metadata
- Authors
- Dawwas, G. K., Brown, J., Dietrich, E., & Park, H.
- Affiliations
- University of Florida (US)
- Corresponding author
- Park, Haesuk
- Venue
- The Lancet Haematology
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 6
- Issue
- 1
- Pages
- e20-e28
- ISSN
- 2352-3026 (ISSN-L)
- OpenAlex
- W2905543904
- Cited by
- 84
- References
- 27
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 4 · 2023: 10 · 2022: 12 · 2021: 13 · 2020: 18 · 2019: 17
- FWCI
- 11.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet Haematology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Association of University Women
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- apixaban, rivaroxaban, venous thromboembolism, recurrent venous thromboembolism, major bleeding, direct oral anticoagulants, deep vein thrombosis, pulmonary embolism, propensity score matching
- MeSH terms
- Rivaroxaban, Anticoagulants, Female, Humans, Male, Middle Aged, Pyrazoles, Pyridones, Retrospective Studies, Cohort Studies, Venous Thromboembolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. https://app.cochat.ai/papers/10.1016/s2352-3026(18)30191-1
- The paper
- Dawwas, G. K., Brown, J., Dietrich, E., & Park, H. (2019). Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. The Lancet Haematology. https://doi.org/10.1016/s2352-3026(18)30191-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.